Vaxcyte, Inc. Form 4 Filings

Vaxcyte, Inc. (PCVX) SVP, Finance & CAO Elvia Cowan exercised a fully vested and exercisable stock option for 19,000 shares on October 5, 2026, at a $25.92 exercise price, acquiring 19,000 common shares. She sold 19,000 shares that day at $86.74 per share pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the exercise, Cowan reported 74,068 shares subject to stock options.

Vaxcyte, Inc. EVP, Chief Scientific Officer and COO Jim Wassil exercised options to acquire 2,250 common shares at $5.35 per share on October 1, 2026. He also sold 2,155 shares at a weighted-average $56.654 and 95 shares at a weighted-average $57.094. The sales were made under a Rule 10b5-1 trading plan adopted December 9, 2025. The derivative-security row reports 64,398 stock options following the transaction.

Vaxcyte, Inc. (PCVX) reports that Chief Executive Officer and director Grant Pickering surrendered 17,056 shares of Common Stock on September 8, 2026 to cover applicable tax withholding obligations arising from the vesting of restricted stock units, at a reference price of $60.36 per share. After this tax-withholding disposition, he directly holds 429,902 shares of Vaxcyte common stock and also has indirect holdings through trusts established for his son and daughter.

Vaxcyte, Inc. (PCVX) reported that President and CFO Andrew Guggenhime had 7,155 shares of common stock withheld on September 8, 2026 to cover tax liabilities arising from the vesting of restricted stock units, at a reference price of $60.36 per share. After this tax-withholding disposition, he holds 95,316 shares directly, plus 61,850 shares held indirectly through ALG 2025 GRAT Holdings LLC, a grantor retained annuity trust for which he is annuitant and trustee.

Vaxcyte, Inc. (PCVX) reported that Chief Technical Ops Officer Harpreet S. Dhaliwal had 7,651 shares of common stock surrendered on September 8, 2026 to cover tax withholding obligations arising from vesting RSUs. The transaction was a share disposition for tax purposes, leaving 68,085 shares held directly after the event. No Rule 10b5-1 trading plan is reported for this transaction.

Vaxcyte, Inc. (PCVX) reported that Elvia Cowan, its Senior Vice President, Finance and Chief Accounting Officer, surrendered 1,327 shares of common stock on September 8, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. The shares were valued at $60.36 per share for this purpose, and Cowan now holds 27,860 shares of Vaxcyte common stock directly. This was a tax-withholding share disposition, not an open-market sale, and no Rule 10b5-1 trading plan is reported.

Vaxcyte, Inc. (PCVX) executive Jim Wassil, EVP, Chief Scientific Officer and COO, reported selling a total of 2,715 shares of common stock in open-market transactions on September 4 and 9, 2026, at weighted-average prices around $61.16 and $59.52, respectively, under a Rule 10b5-1 trading plan adopted on December 9, 2025. On September 8, 2026, 5,459 shares were surrendered to the issuer to cover tax withholding obligations upon RSU vesting.

Vaxcyte, Inc. (PCVX) reported that Chief Medical Officer Luis Jodar received new equity awards on September 4, 2026. He was granted 52,632 restricted stock units, each representing one share of common stock, and a stock option for 88,254 shares at an exercise price of $61.16 per share, expiring September 4, 2036. The RSUs vest 25% on September 7, 2027 and 12.5% every six months thereafter, and the option vests 25% on August 31, 2027 and monthly thereafter, in each case subject to his continued service. No Rule 10b5-1 trading plan is reported.

Vaxcyte, Inc. (PCVX) chief operating officer Jim Wassil reported an option exercise and related share transactions. On September 1, 2026 he exercised 2,250 stock options at $5.35 per share into common stock, then sold 3,477 shares around $61 per share in open-market transactions under a Rule 10b5-1 trading plan. On August 31 and September 2, 2026, a total of 2,705 shares of common stock were withheld or surrendered at prices near $61 solely to cover tax liabilities from vesting RSUs. Following the exercise, Wassil held 66,648 stock options of the same series directly.

Vaxcyte, Inc. (PCVX) director and chief executive officer Grant Pickering reported two Form 4 transactions involving Common Stock that were dispositions solely to cover tax withholding on vested restricted stock units. On August 31, 2026, 2,862 shares were surrendered at $60.74 per share, and on September 2, 2026, 3,427 shares were surrendered at $61.58 per share, both to the issuer for tax obligations. No Rule 10b5-1 trading plan is reported, and additional shares are held indirectly through trusts for the benefit of his son and daughter.

Vaxcyte, Inc. (PCVX) reported that its president and chief financial officer, Andrew Guggenhime, had 2,705 shares of common stock surrendered on August 31 and September 2, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. These dispositions were made by delivering or withholding shares rather than through open-market sales, and no Rule 10b5-1 trading plan is reported. Separately, 61,850 shares of common stock are shown as held indirectly through ALG 2025 GRAT HOLDINGS LLC, a grantor retained annuity trust–related entity for which Guggenhime is annuitant and trustee.

Vaxcyte, Inc. (PCVX) reported that Chief Technical Ops Officer Harpreet S. Dhaliwal surrendered shares of common stock to the company to cover tax withholding on vested RSUs. On August 31, 2026, 361 shares were withheld at $60.74 per share, and on September 2, 2026, 659 shares were withheld at $61.58 per share. These are non-market, code F transactions, and no Rule 10b5-1 trading plan is reported.

Vaxcyte, Inc. (PCVX) reported that Elvia Cowan, SVP, Finance & CAO, had two Form 4 transactions consisting of shares of common stock surrendered to cover tax withholding on vested restricted stock units. On August 31 and September 2, 2026, a total of 569 shares were withheld for this purpose.

Vaxcyte, Inc. executive Harpreet S. Dhaliwal, Chief Technical Ops Officer, reported an option exercise and related share sale. On August 5, 2026, he exercised stock options covering 17,000 shares of common stock at an exercise price of $24.79 per share from a fully vested option grant, and reported holding 28,000 stock options after the transaction.

The same day, he sold 17,000 common shares at a weighted-average price of $55.004 per share, with trade prices ranging from $55.00 to $55.255, under a Rule 10b5-1 trading plan adopted on April 6, 2026. His reported direct common stock position includes 780 shares acquired through the Employee Stock Purchase Plan on May 15, 2026.

Vaxcyte, Inc. chief operating officer Jim Wassil exercised stock options for 2,250 shares of common stock at $5.35 per share on August 3, 2026, then sold a total of 2,250 shares in two transactions at weighted-average prices of $53.502 and $54.089 per share under a Rule 10b5-1 trading plan. The exercised options were fully vested and exercisable, and 68,898 stock options remained beneficially owned afterward. His reported direct holdings include 781 shares acquired through the company’s employee stock purchase plan on May 15, 2026.

Vaxcyte, Inc. president and CFO Andrew Guggenhime exercised stock options for 10,000 shares of common stock at $5.35 per share on August 3, 2026, then reported sales of 6,956 shares at a weighted-average price of $53.761 and 3,044 shares at $54.178 under a Rule 10b5-1 trading plan adopted March 4, 2026. After these transactions he directly held 216,827 stock options and indirectly held 61,850 common shares through ALG 2025 GRAT HOLDINGS LLC, while his direct common stock position includes 781 shares acquired under the Employee Stock Purchase Plan on May 15, 2026.

Vaxcyte, Inc. chief executive Grant Pickering exercised stock options for 16,198 shares of common stock at an exercise price of $2.03 per share on July 27, 2026. He then sold 18,198 common shares in market transactions at prices between $54.77 and $56.18 per share under a Rule 10b5-1 trading plan, including sales by trusts for his children. After the derivative transaction, 137,000 option shares remain exercisable.

Vaxcyte, Inc. director John Markels reported a compensatory grant of 23,029 stock options, each exercisable for one share of common stock at an exercise price of $56.04 per share. The options expire on July 16, 2036 and vest over 36 months: one-third vests on July 16, 2027, and the remaining portion vests in equal monthly installments thereafter, subject to his continuous service. Following this award, he holds 23,029 derivative securities directly.

Vaxcyte, Inc. President and CFO Andrew Guggenhime reported an option exercise and related share sales. He exercised stock options to acquire 10,000 shares of Common Stock at $5.35 per share, then sold 10,000 shares in two open-market transactions.

The sales covered 2,087 shares at a weighted-average price of about $57.76 and 7,913 shares at a weighted-average price of about $57.16, with actual prices ranging from $56.595 to $58.32, pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026. Following these transactions, he holds 104,395 shares directly and 61,850 shares indirectly through ALG 2025 GRAT Holdings LLC.

Vaxcyte, Inc. chief operating officer Jim Wassil reported a set of transactions in the company’s common stock. He sold a total of 2,250 shares in open-market trades at weighted-average prices around the mid‑$50s per share under a Rule 10b5-1 trading plan adopted on December 9, 2025. On the same date, he exercised a stock option to acquire 516 shares at an exercise price of $5.35 per share, reducing his remaining option position. After these trades, he continues to hold a substantial stake of more than 150,000 shares of common stock, along with tens of thousands of remaining stock options.

Vaxcyte, Inc. director and CEO Grant Pickering reported open-market sales of 24,237 shares of Common Stock on June 26, 2026. The transactions included sales by trusts for the benefit of his son and daughter, as well as shares held directly. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026. After the direct sales, he held 468,020 shares directly.

Vaxcyte, Inc. director Moncef Slaoui reported receiving a new stock option grant covering 26,061 shares of common stock. The option has an exercise price of $52.11 per share and expires on June 22, 2036.

The award was granted at no cost and is classified as a compensation-related grant, not an open‑market purchase or sale. According to the vesting terms, one‑third of the option will vest on June 17, 2027, with the remaining portion vesting in equal monthly installments over the following 24 months, contingent on his continued service with the company.

Vaxcyte, Inc. director and CEO Grant Pickering reported a mix of stock option exercise and share sales in Common Stock on June 18, 2026. He exercised stock options for 225 shares at $1.79 per share and separately reported open-market sales totaling 24,461 shares at prices around $52.50 per share.

Two 1,000-share sales were attributed to children’s trusts that hold shares for his son and daughter, while 22,461 shares were sold from his direct holdings. After these transactions, Pickering holds 496,939 shares directly and 135,215 shares indirectly through trusts. The filing notes the sales were completed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.

Vaxcyte, Inc. President and CFO Andrew Guggenhime reported a combination of option exercise and share sale. On June 18, 2026, he exercised stock options for 10,000 shares of common stock at $5.35 per share and sold 10,000 shares of common stock at $53.00 per share in an open-market transaction.

The filing notes that the sale was effected under a Rule 10b5-1 trading plan adopted March 4, 2026. Following these transactions, he holds 104,395 shares of common stock directly and 61,850 shares indirectly through ALG 2025 GRAT HOLDINGS LLC, tied to a grantor retained annuity trust. The option related to these 10,000 shares is fully vested and exercisable and has now been exercised.

Vaxcyte, Inc. director Carlos V. Paya reported new equity awards. He received 2,265 shares of Common Stock underlying restricted stock units (RSUs) at no cost and 11,389 stock options with a $49.56 exercise price, both granted as compensation.

The RSUs fully vest on the earlier of June 15, 2027 or the day before the next annual stockholder meeting, with delivery deferred under Vaxcyte's Nonqualified RSU Deferral Program for Non-Employee Directors. The options vest monthly on the same schedule and expire on June 15, 2036.

Following these awards, Paya directly holds 6,856 shares of Common Stock and has 5,625 shares held indirectly through a family trust.

Vaxcyte director Olivier Brandicourt received new equity awards consisting of restricted stock units (RSUs) and stock options. He was granted 2,194 RSUs, each representing one share of Vaxcyte common stock. These RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to his continuous service.

He also received stock options for 11,034 shares of common stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These options vest monthly and will be fully vested on the same earlier-of-2027-or-next-meeting schedule. Following the RSU grant, he directly holds 4,699 common shares.

Vaxcyte, Inc. director John Furey received equity awards as part of his compensation. He acquired 2,265 shares of Common Stock in the form of restricted stock units that will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to his continuous service. Following this grant, he directly holds 5,306 shares of Common Stock.

Furey also received a stock option for 11,389 shares of Common Stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These option shares vest monthly and will be fully vested on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to his continued service.

Vaxcyte, Inc. director Lee Jacks reported equity awards consisting of restricted stock units and stock options. He received 2,265 RSUs, each representing one share of common stock, and 11,389 stock options with an exercise price of $49.5600 per share.

The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to acceleration and his continuous service. The stock options vest monthly on the same overall schedule and expire on June 15, 2036. Following the grant, Jacks directly holds 6,856 shares of common stock, plus the newly granted options.

Vaxcyte, Inc. director Halley E. Gilbert received new equity awards from the company. He was granted 2,265 restricted stock units, each representing one share of common stock, which will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to his continuous service.

He also received stock options for 11,389 shares of common stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These options vest monthly and will be fully vested on the same earlier-of-2027-or-next-meeting schedule. Following the RSU grant, he directly holds 12,481 shares of common stock.

Vaxcyte, Inc. director Teri Loxam reported receiving equity-based compensation. The filing shows a grant of 2,265 shares of Common Stock underlying restricted stock units (RSUs) and a separate grant of stock options covering 11,389 shares of Common Stock.

The RSUs vest in full on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to continuous service, and delivery has been deferred under the company’s Nonqualified RSU Deferral Program for Non-Employee Directors. The stock options have an exercise price of $49.56 per share, vest monthly on the same schedule, and expire on June 15, 2036. Following the RSU grant, Loxam directly holds 12,481 shares of Common Stock.

Vaxcyte, Inc. director Anne S. Drapeau reported equity compensation awards rather than market trades. She received 2,265 shares of Common Stock in the form of restricted stock units, bringing her direct Common Stock holdings to 12,481 shares after the grant.

She was also granted a stock option for 11,389 shares of Common Stock at an exercise price of $49.56 per share, expiring on June 15, 2036. Both the RSUs and the option are scheduled to vest fully on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration and her continuous service.

Vaxcyte, Inc. director Heath Lukatch reported equity compensation awards rather than open-market trades. He received 2,265 shares of Common Stock through restricted stock units, with each RSU representing one share, and 11,389 stock options to buy Common Stock at an exercise price of $49.56 per share.

The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to continuous service and possible acceleration. The stock options vest monthly on the same schedule and expire on June 15, 2036. Following the RSU grant, Lukatch directly holds 19,481 shares of Common Stock.

Vaxcyte, Inc. Chief Operating Officer Jim Wassil reported open-market sales of a total of 2,250 shares of common stock on June 1, 2026, at weighted-average prices around $50 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025.

After these sales, Wassil continues to hold about 158,000 shares of Vaxcyte common stock directly, indicating that the trades represent a small portion of his overall position and appear to be routine, pre-planned portfolio management rather than a change in fundamental outlook.

Vaxcyte, Inc. chief operating officer Jim Wassil reported an open-market sale of 2,250 shares of common stock at a weighted-average price of $56.831 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, he directly holds 160,744 shares of Vaxcyte common stock.

Vaxcyte, Inc. SVP, Finance & CAO Elvia Cowan exercised stock options and then sold the resulting shares. On 2026-04-07, she exercised options for 3,000 shares of common stock at an exercise price of $25.92 per share and acquired 3,000 shares.

The same day, she sold 3,000 shares of common stock at $60.00 per share in an open-market transaction, leaving her with 28,975 shares held directly after the sale. The filing notes that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025, indicating the transactions were scheduled in advance.

Vaxcyte, Inc. chief operating officer Jim Wassil reported open-market sales of 2,250 shares of common stock. On April 1, 2026, he sold 1,412 shares at a weighted-average price of $58.138 and 838 shares at a weighted-average price of $58.932.

After these sales, he directly owned 162,994 shares of Vaxcyte common stock. The transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. A footnote also describes prior share transfers to his ex-spouse pursuant to a divorce settlement domestic relations order.

Vaxcyte, Inc. SVP, Finance & CAO Elvia Cowan reported selling 1,892 shares of common stock in open-market transactions. The sales on March 17, 2026 were executed under a Rule 10b5-1 trading plan adopted on December 8, 2025, with weighted-average prices of $55.387 and $56.263 per share.

After these sales, Cowan directly holds 28,975 shares of Vaxcyte common stock. The footnotes state that all transactions were within a pre-set trading plan and that no other shares subject to a January 29, 2026 lock-up agreement were sold.

Vaxcyte, Inc. Chief Technical Ops Officer Harpreet S. Dhaliwal surrendered 604 shares of common stock on March 9, 2026 to cover tax withholding obligations from vesting restricted stock units. The shares were delivered to the company rather than sold in the market, and Dhaliwal continues to hold 75,976 shares directly.

Vaxcyte, Inc. director and chief executive officer Grant Pickering reported a tax-related share disposition. On March 9, 2026, he surrendered 3,685 shares of Common Stock at $59.32 per share to cover tax withholding obligations from vesting restricted stock units.

After this withholding event, he directly held 496,939 shares of Vaxcyte common stock. Additional shares are held indirectly through trusts for the benefit of his children, and the filing notes that no other common shares subject to a January 29, 2026 lock-up agreement were sold.

Vaxcyte, Inc. president and CFO Andrew Guggenhime reported a routine tax-withholding share disposition tied to RSU vesting. He surrendered 1,021 shares of common stock at $59.32 per share to cover tax obligations when restricted stock units vested, rather than selling shares in the open market.

After this transaction, he directly holds 104,395 common shares. An additional 61,850 shares are held indirectly through ALG 2025 GRAT HOLDINGS LLC, a grantor retained annuity trust entity for which he is annuitant and trustee. The filing states that no other locked-up shares were sold by him.

Vaxcyte, Inc. SVP, Finance & CAO Elvia Cowan exercised stock options and sold shares in a routine, partially pre-planned transaction. Cowan exercised options for 2,500 shares of common stock at $25.92 per share and then sold 2,500 shares at an average price of $58.5927 per share.

The filing also shows 495 shares of common stock were surrendered to Vaxcyte to cover tax withholding obligations upon RSU vesting, which is described as a non-market disposition. After these transactions, Cowan directly holds 30,867 shares of Vaxcyte common stock. The sale was carried out under a Rule 10b5-1 trading plan adopted on December 8, 2025, indicating it was pre-scheduled rather than opportunistic.

Vaxcyte, Inc. chief operating officer Jim Wassil reported recent stock transactions. On March 9, 2026, 975 shares of common stock were surrendered to the company to cover tax withholding obligations upon RSU vesting, which is an automatic, non-market disposition.

On March 10, 2026, he completed two open-market sales totaling 7,395 shares of common stock at weighted-average prices of $58.316 and $59.160. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. After these transactions, he directly holds 166,818 shares of Vaxcyte common stock, indicating that he retains a substantial equity position.

Vaxcyte, Inc. reported insider equity transactions by Elvia Cowan, its SVP, Finance & CAO. On February 26, 2026, Cowan received a grant of stock options for 17,855 shares and a separate award of 10,681 restricted stock units, each RSU representing one share of common stock.

The RSUs vest as to one quarter of the shares on September 7, 2026, then one eighth every six months, subject to continued service. The new option vests as to one forty-eighth of the shares on March 26, 2026, and monthly thereafter, also subject to continued service.

On the same date, Cowan exercised 7,716 stock options at $25.92 per share, receiving the same number of common shares. On February 28 and March 2, 2026, a total of 569 shares were surrendered at $61.98 per share to cover tax withholding on vested RSUs. After these transactions, Cowan directly owned 31,362 common shares.

Vaxcyte, Inc. reported that President and CFO Andrew Guggenhime received equity awards and had shares withheld to cover taxes. On February 26, 2026, he was granted 44,864 shares of common stock in the form of RSUs and 74,993 stock options. On February 28 and March 2, 2026, a total of 1,907 shares of common stock were surrendered to the company to satisfy tax withholding on RSU vesting. He also reports indirect ownership of 61,850 shares held by ALG 2025 GRAT HOLDINGS LLC, a grantor retained annuity trust for which he is annuitant and trustee.

Vaxcyte, Inc. director and chief executive officer Grant Pickering reported equity compensation grants and related tax-withholding share dispositions. On February 26, 2026, he received a grant of 105,110 shares of Common Stock and a stock option for 175,698 shares, both at a stated price of $0.00 per share, as awards. The option vests as to 1/48 of the shares on March 26, 2026, then 1/48 monthly thereafter, subject to continued service. The common stock award represents RSUs that vest 1/4 on September 7, 2026 and 1/8 every six months after, also contingent on continued service. To cover tax withholding from RSU vesting, he surrendered 2,531 shares on March 2, 2026 and 2,863 shares on February 28, 2026 at $61.98 per share. After these transactions, he directly owned just over 500,000 Common Stock shares, with additional indirect holdings reported through trusts for the benefit of his son and daughter.

Vaxcyte, Inc. reported insider equity activity by Chief Technical Ops Officer Harpreet S. Dhaliwal. On February 26, 2026, Dhaliwal received grants of 53,409 shares of common stock and 46,424 stock options, both at a reported price of $0.00 per share as awards. The common stock grant represents restricted stock units that vest over time starting September 7, 2026. On February 28 and March 2, 2026, a total of 757 shares of common stock were disposed of at $61.98 per share to cover tax withholding obligations upon RSU vesting. After these transactions, Dhaliwal directly held 76,580 shares of common stock.

Vaxcyte, Inc. chief operating officer Jim Wassil reported equity compensation activity and related tax withholdings. He received 32,045 restricted stock units at a grant price of $0.00 per share, plus an additional 5,102 RSUs at $61.74 per share. He was also granted a stock option for 53,566 shares at a $0.00 exercise price, vesting in monthly installments beginning March 26, 2026.

To cover tax obligations from RSU vesting, shares of common stock were surrendered back to the company: 1,900 shares at $61.74 per share, 898 shares at $61.98 per share, and 1,009 shares at $61.98 per share. After these transactions, he directly owned 175,188 shares of common stock.

Vaxcyte, Inc. director and CEO Grant Pickering reported an internal share transfer involving company common stock. On January 14, 2026, an entity associated with him transferred 100,000 shares of common stock to an irrevocable trust for estate planning purposes, with a reported price of $0 per share, indicating this was not an open‑market sale. The footnote explains that he no longer has a pecuniary interest in those shares and therefore disclaims beneficial ownership.

Following the transaction, 400,908 common shares are reported as directly owned. In addition, 136,215 common shares are held by a trust for the benefit of his son and another 136,215 common shares are held by a trust for the benefit of his daughter, both reported as indirectly owned through children’s trusts.

Vaxcyte, Inc. reported an insider share transfer involving its President and CFO, Andrew Guggenhime. On 01/14/2026, 61,850 shares of common stock were moved from his direct holdings to ALG 2025 GRAT HOLDINGS LLC at a reported price of $0 per share. The filing notes that he is the sole member and manager of this LLC, and that the LLC is wholly owned by a grantor retained annuity trust for which he is the sole annuitant and trustee.

After the transaction, Guggenhime directly held 62,459 shares of Vaxcyte common stock and indirectly held 61,850 shares through ALG 2025 GRAT HOLDINGS LLC.